Literature DB >> 1977520

Sympathomimetic amines and cardiac arrhythmias.

E Oppenheimer1, E Akavia, S Shavit, A D Korczyn.   

Abstract

STUDY
OBJECTIVE: The aim was to investigate the arrhythmogenic properties of several sympathomimetic amines and their antagonism by adrenergic blocking drugs.
DESIGN: Arrhythmia was induced by the investigated drugs, injected intravenously: adrenaline (ADR); noradrenaline (NA); phenylephrine (PE); isoprenaline (IP); terbutaline (Tb) and salbutamol (Sb). ADR and PE were also tested for their arrhythmogenic properties after the administration of the adrenergic antagonists propranolol, phentolamine, or both. The dose required to induce arrhythmia and the proportion of animals that developed arrhythmia at a given dose were recorded.
SUBJECTS: 63 anaesthetised cats of either sex, weight 2.0-4.3 kg, were used. MEASUREMENTS AND
RESULTS: The electrocardiogram was recorded continuously. The arrhythmogenic potency sequence (expressed as arrhythmogenic dose, AD50 in micrograms) was: ADR 16; NA 24; PE 75; IP 133; Tb 500; Sb greater than 1000. The arrhythmogenic efficacy (in %) was: ADR 97; NA 91; PE 90; IP 82; Tb 50; and Sb 0. Propranolol and phentolamine were both effective in reducing the arrhythmogenic effects of ADR and PE. However, their combined administration was most effective and abolished the arrhythmias.
CONCLUSIONS: Arrhythmogenicity is a property of sympathomimetic amines with either alpha or beta adrenergic effects, but simultaneous activation of both types of receptors is required for maximal manifestations. Similarly, antagonism at both sites is necessary in order to abolish arrhythmias induced by sympathomimetic amines completely.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977520     DOI: 10.1093/cvr/24.9.754

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  1 in total

1.  A shocking case of pseudoephedrine use.

Authors:  D R Goldstein; A E Epstein
Journal:  J Interv Card Electrophysiol       Date:  1999-12       Impact factor: 1.900

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.